UTI Healthcare Fund · Regular · Growth
NAV
₹334.5099
as of 31 Jul 2026
Expense Ratio
2.27%
AUM
₹1,175 Cr
Lumpsum returns (CAGR)
- 1Y
- +12.75%
- 3Y
- +23.26%
- 5Y
- +14.70%
- Since Inception
- +13.21%
SIP returns (XIRR)
- 1Y
- +27.66%
- 3Y
- +20.13%
- 5Y
- +20.39%
- Since Inception
- +15.46%
Returns calculated from 16 September 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
What history actually did — last 10 years (Aug 2016 – Jul 2026)
A ₹5,000 monthly SIP for the last 10 years (Aug 2016 – Jul 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹15,51,880 today — ₹5,95,000 invested, 18.5% XIRR.
₹5,95,000
Invested
₹15,51,880
Value today
18.5%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Aug 2016 – Jul 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,58,054 today (13.6% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Aug 2016 would still hold ₹20,28,664.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹15,51,880 in this fund vs ₹12,17,407 in the benchmark — outperformance of ₹3,34,473.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Aug 2016 – Jul 2026) (22 Mar 2020) would be ₹4,53,305 today (4.53×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.51
Sharpe Ratio
+0.11
Alpha
0.23
Beta
0.47
Sortino
14.10%
Std Dev
-11.26%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 May 2026- Pharmaceuticals & Biotechnology68.65%
- Healthcare Services23.66%
- Chemicals & Petrochemicals1.72%
- Healthcare Equipment & Supplies1.03%
Each sector links to the mutual funds most exposed to it.
Thinking about UTI Healthcare Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceuticals Industries8.54%
- 2Ajanta Pharma Ltd.5.08%
- 3Divis Laboratories Ltd.4.74%
- 4Gland Pharma Ltd.4.11%
- 5Caplin Point Laboratories Ltd4.02%
- 6Lupin Ltd.3.77%
- 7Apollo Hospitals Enterprise Lt3.52%
- 8Alkem Laboratories Ltd3.14%
- 9Dr Reddys Laboratories Ltd.3.01%
- 10Max Healthcare Institute Ltd2.98%
Investment Objective
UTI Healthcare Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
UTI Healthcare Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by UTI Mutual Fund. The fund has been operational for over 26 years. It manages assets worth ₹1,175 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE Healthcare TRI. The current expense ratio is 2.27%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations